- Home
- DCTH vs HFRO Comparison
DCTH vs HFRO Comparison
Compare DCTH & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- HFRO
- Stock Information
- Founded
- DCTH 1988
- HFRO 2000
- Country
- DCTH United States
- HFRO United States
- Employees
- DCTH N/A
- HFRO N/A
- Industry
- DCTH Medical/Dental Instruments
- HFRO Finance/Investors Services
- Sector
- DCTH Health Care
- HFRO Finance
- Exchange
- DCTH Nasdaq
- HFRO Nasdaq
- Market Cap
- DCTH 388.3M
- HFRO 362.0M
- IPO Year
- DCTH N/A
- HFRO N/A
- Fundamental
- Price
- DCTH $8.62
- HFRO $6.47
- Analyst Decision
- DCTH Strong Buy
- HFRO
- Analyst Count
- DCTH 5
- HFRO 0
- Target Price
- DCTH $22.60
- HFRO N/A
- AVG Volume (30 Days)
- DCTH 1.3M
- HFRO 179.8K
- Earning Date
- DCTH 11-04-2025
- HFRO 01-01-0001
- Dividend Yield
- DCTH N/A
- HFRO 8.87%
- EPS Growth
- DCTH N/A
- HFRO N/A
- EPS
- DCTH 0.03
- HFRO N/A
- Revenue
- DCTH $79,603,000.00
- HFRO N/A
- Revenue This Year
- DCTH $135.11
- HFRO N/A
- Revenue Next Year
- DCTH $36.30
- HFRO N/A
- P/E Ratio
- DCTH $250.39
- HFRO N/A
- Revenue Growth
- DCTH 251.54
- HFRO N/A
- 52 Week Low
- DCTH $8.39
- HFRO $4.24
- 52 Week High
- DCTH $18.23
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- DCTH 30.11
- HFRO 52.56
- Support Level
- DCTH $9.15
- HFRO $6.44
- Resistance Level
- DCTH $10.03
- HFRO $6.58
- Average True Range (ATR)
- DCTH 0.67
- HFRO 0.13
- MACD
- DCTH -0.21
- HFRO -0.00
- Stochastic Oscillator
- DCTH 5.71
- HFRO 58.69
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.